NCT00742079View on ClinicalTrials.gov

Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

D-cycloserine

Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session

BEHAVIORAL

Cognitive Behavioral Therapy

One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations

Trial Locations (1)

02114

MGH Schizophrenia Program - Freedom Trail Clinic, Boston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00742079 - Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia | Biotech Hunter | Biotech Hunter